I look forward to the information flow and stimulus that may occur from this webinar.
https://www.parentprojectmd.org/eve...erapeutics-phase-ii-trial-final-data-results/
Antisense Therapeutics recently announced that their Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne in non-ambulatory patients has met its primary endpoint, confirming the safety and tolerability of ATL1102 for advancement into a Phase IIb clinical trial. Please join PPMD and Antisense as we host a webinar Wednesday, June 17 at 1 PM ET to discuss Antisense Therapeutics’ clinical program, as well as next steps in the upcoming Phase IIb trial.
Please submit questions in advance to [email protected] (subject line: Antisense Webinar) by Monday, June 15 at 12 PM ET.
Register >
PPMD webinar
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
